Loading data for PCVX — first visit, this takes a few seconds.
Vaxcyte Inc. (PCVX)
NasdaqGS: PCVX
· Real-Time Price · USD
59.84
-1.32 (-2.16%)
At close: Aug 31, 2026, 5:27 PM
The price, the headline numbers and the latest news, in one place.
Vaxcyte Inc. (PCVX) Stock Price, Analysis & Data
-2.16% (1D)
No data available
| Bid | 43.9 |
| Market Cap | 8.99B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -1.06B |
| 1.21 | |
| -7.63 | |
| n/a | |
| -8.37 | |
| P/B (ttm) | 3.17 |
| P/S (ttm) | n/a |
| Earnings Date | Nov 3, 2026 |
| Ask | 76.51 |
| Volume | 759,733 |
| Avg. Volume (20D) | 1,313,279 |
| Open | 61.06 |
| Previous Close | 61.16 |
| Day's Range | 59.48 - 61.80 |
| 52-Week Range | 30.81 - 65.00 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About PCVX
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 12, 2020
Employees 507
Stock Exchange NasdaqGS
Ticker Symbol PCVX
Website https://vaxcyte.com
Financial Performance
In 2025, Vaxcyte's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -766.63M, an increase of 65.25%.
Financial StatementsEarnings Surprise
Vaxcyte has released their quarterly earnings on Aug 5, 2026:
- Revenue of $0 misses estimates by $0, with NaN% YoY growth.
- EPS of -1.97 exceeds estimates by 0.13, with -61.48% YoY decline.
Vaxcyte Inc. is scheduled to release its earnings on Nov 3, 2026, during market hours.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
Page 1 of 2